Exenatide
- TRADE NAMES: Bydureon (Amylin); Byetta (Amylin)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Antidiabetic, Glucagon-like peptide-1 (GLP-1) receptor agonist, Incretin mimetic, Insulin secretagogue
- HALF-LIFE: 2.4 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetaminophen, Alcohol, Antibiotics, Corticosteroids, Lovastatin, Oral Contraceptives, Pegvisomant, Prandial insulin, Somatropin, Sulfonylureas, Thiazide diuretics, Vitamin K antagonists, Warfarin
PREGNANCY CATEGORY: C
Risk of thyroid C-cell tumors with exenatide extended release formulations.
Bydureon is contra-indicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome Type 2.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 12/10/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric